Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

NEW YORK – Immix Biopharma this week said it plans to address various conditions with its autologous CAR T-cell therapy NXC-201 in what it calls its "other serious diseases" strategy. NXC-201 is a ...

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

The firm will use the funds to advance its mRNA therapies, including its lead candidate STX-001 for treating melanoma and triple-negative breast cancer.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

NEW YORK – Patients with previously treated, advanced urothelial cancer with high expression of PPARG are starting to receive Flare Therapeutics' investigational drug FX-909 in a Phase Ib trial, the ...

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.